Skip to main content
Log in

11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to compare the prognostic value of 11C-methionine (MET) and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in glioma patients.

Methods

The study population comprised 47 patients with gliomas (19 glioblastoma, 28 others). Pretreatment magnetic resonance imaging, MET PET and FDG PET were performed within a time interval of 2 weeks in all patients. The uptake ratio and standard uptake values were calculated. Univariate and multivariate analyses were done to determine significant prognostic factors. Ki-67 index was measured by immunohistochemical staining, and compared with FDG and MET uptake in glioma.

Results

Among the several clinicopathological prognostic factors, tumour pathology (glioblastoma or not), age (≥60 or <60 years), Karnofsky performance status (KPS) (≥70 or <70) and MET PET (higher uptake or not compared with normal cortex) were found to be significant predictors by univariate analysis. In multivariate analysis, tumour pathology, KPS and MET PET were identified as significant independent predictors. The Ki-67 proliferation index was significantly correlated with MET uptake (r=0.64), but not with FDG uptake.

Conclusion

Compared with FDG PET in glioma, MET PET was an independent significant prognostic factor and MET uptake was correlated with cellular proliferation. MET PET may be a useful biological prognostic marker in glioma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1a–c
Fig. 2a,b
Fig. 3a,b
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Winger MJ, Madonald DR, Cairncross JG. Supratentorial anaplastic glioma in adults. J Neurosurg 1989;71:487–93.

    CAS  PubMed  Google Scholar 

  2. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190–8.

    CAS  Google Scholar 

  3. Russell D, Rubinstein L. Tumours of central neuroepithelial origin. In: Rubinstein LJ, editor. Pathology of tumours of the central nervous system. Baltimore: Williams & Wilkins; 1989. p. 83–350.

    Google Scholar 

  4. Bampoe JO, Bauman G, Cairncross JG. Adult low-grade glioma: natural history, prognostic factors, and timing of treatment. In: Rock JP, Rosenblum ML, Shaw EG, Cairncross JG, editors. The practical management of low-grade primary brain tumors. Philadelphia: Williams & Wilkins; 1999. p. 135–48.

    Google Scholar 

  5. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 2000;54:1442–8.

    CAS  PubMed  Google Scholar 

  6. Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytoma. Neurosurgery 1996;38:872–9.

    CAS  PubMed  Google Scholar 

  7. Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol 1997;15:3129–40.

    CAS  PubMed  Google Scholar 

  8. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62:1074–8.

    CAS  PubMed  Google Scholar 

  9. De Witte O, Lefranc F, Levivier M, Salmon I, Brotchi J, Goldman S. FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 2000;49:157–63.

    Article  PubMed  Google Scholar 

  10. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623–48.

    CAS  PubMed  Google Scholar 

  11. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972–80.

    CAS  PubMed  Google Scholar 

  12. Schober O, Duden C, Meyer GJ, Muller JA, Hundeshagen H. Non-selective transport of [11C-methyl]-l-and d-methionine into a malignant glioma. Eur J Nucl Med 1987;13:103–5.

    CAS  PubMed  Google Scholar 

  13. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85.

    CAS  PubMed  Google Scholar 

  14. Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, Syrota A. [11C]l-methionine uptake in gliomas. Neurosurgery 1989;25:720–8.

    CAS  PubMed  Google Scholar 

  15. Chung JK, Kim YK, Kim SK, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:176–82.

    Article  CAS  PubMed  Google Scholar 

  16. De Witte O, Goldberg I, Wilker D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746–50.

    PubMed  Google Scholar 

  17. Ishiwata K, Ido T, Vaalburg W. Increased amounts of d-enantiomer dependent on alkaline concentration in the synthesis of l-[methyl-11C]methionine. Appl Radiat Isot 1988;39:310–4.

    Google Scholar 

  18. Vecht C, Acesaat CJJ, Van Putten WLJ, et al. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 1990;53:466–71.

    Google Scholar 

  19. Albert FK, Forsting M, Sator K, et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth prognosis. Neurosurgery 1994;34(6):45–61.

    Google Scholar 

  20. Walker MD, Green SB, Byar DP, et al. Randomized comparison of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303(7):1323–9.

    CAS  PubMed  Google Scholar 

  21. Levin VA, Wara WM, Davis RL, et al. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 1985;63:218–23.

    CAS  PubMed  Google Scholar 

  22. Langen KJ, Muhlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH. Transport mechanisms of 3-[123I]iodo-alpha-methyl-l-tyrosine in a human glioma cell line: comparison with [3H]methyl-l-methionine. J Nucl Med 2000;41:1250–5.

    CAS  PubMed  Google Scholar 

  23. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47–52.

    CAS  PubMed  Google Scholar 

  24. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23:865–70.

    Article  CAS  PubMed  Google Scholar 

  25. Oshida M, Uno K, Suzuki M, et al. Predicting the prognosis of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-d-glucose. Cancer 1998;82:2227–34.

    Article  CAS  PubMed  Google Scholar 

  26. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med 1997;38:1907–11.

    CAS  PubMed  Google Scholar 

  27. Miyazawa H, Arai T, Ito M, Hara T. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med 1993;34:1886–91.

    CAS  PubMed  Google Scholar 

  28. Sato N, Suzuki M, Kuwata N, Kuroda K, Wada T, Beppu T, et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 1999;22(4):210–4.

    Article  CAS  PubMed  Google Scholar 

  29. Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001;15:471–86.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to June-Key Chung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, S., Chung, JK., Im, SH. et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 32, 52–59 (2005). https://doi.org/10.1007/s00259-004-1598-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1598-6

Keywords

Navigation